BioHarvest outlines plant-cell platform scaling at Canaccord conference

BioHarvest Sciences Inc. outlined plans to scale its proprietary plant-cell cultivation platform during a presentation at the Canaccord Growth Conference on Tuesday.

The company, which focuses on producing high-value compounds through plant-cell biotechnology, highlighted its strategy to expand production capacity and accelerate commercialization efforts. BioHarvest’s platform leverages controlled-environment cultivation to generate compounds such as cannabinoids and other bioactives without reliance on traditional agricultural methods.

Management emphasized the scalability of the technology, noting potential applications across pharmaceuticals, nutraceuticals, and cosmetics. The company aims to meet growing demand for natural, non-GMO ingredients while reducing supply chain vulnerabilities associated with conventional farming.

BioHarvest also discussed ongoing research initiatives and partnerships aimed at validating the platform’s efficacy and cost-competitiveness. The company reiterated its long-term growth objectives, including revenue targets and timeline milestones for market expansion.

Analysts at the conference raised questions about regulatory pathways and production timelines, to which BioHarvest provided detailed responses regarding compliance strategies and phased deployment plans.